MADIT SICD

• Research type

  Research Study

• Full title

  Multicenter Automatic Defibrillator Implantation Trial with Subcutaneous Implantable Cardioverter Defibrillator

• IRAS ID

  239291

• Contact name

  Amir Zaidi

• Contact email

  Amir.Zaidi@mft.nhs.uk

• Sponsor organisation

  Guidant Europe NV, A wholly-owned indirect subsidiary of Boston Scientific Corporation

• Clinicaltrials.gov Identifier

  NCT02787785

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  8 years, 11 months, 30 days

• Research summary

  The MADIT SICD study aims to demonstrate that patients with diabetes that have suffered a myocardial infarction (MI) will benefit from implantable cardioverter defibrillator (ICD) implantation, even when they have a preserved left ventricular ejection fraction (LVEF) - That is the quantity of blood pumped for each heart beat. Patient in this study will receive a sub-cutaneaous ICD (S-ICD). It is hypothesised that those patients randomised to the implant group will demonstrate a higher survival rate than those that do not receive an ICD/S-ICD.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  18/NW/0280

• Date of REC Opinion

  3 May 2018

• REC opinion

  Favourable Opinion